PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.

NACompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

April 20, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2020

Conditions
Myelodysplastic Syndromes
Interventions
OTHER

research of disease-related factors

included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations

OTHER

research of comorbidities

HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G

OTHER

physical performance

Activities of Daily Living and physical performance

Trial Locations (31)

Unknown

Hôpital Sud, Amiens

Chu Angers, Angers

CH Annecy, Annecy

CH Henri Duffaut, Avignon

CH Blois, Blois

CH Boulogne sur mer, Boulogne-sur-Mer

CH Sud Francillien, Corbeil-Essonnes

CHU Henri Mondor, Créteil

CHU Albert Michallon, Grenoble

CH Versailles, Le Chesnay

CH du Mans, Le Mans

CH de Lens, Lens

Hôpital saint vincent de paul - Institut Catholique, Lille

CHU Limoges, Limoges

Ch Lyon Sud, Lyon

Institut Paoli Calmette, Marseille

CH de Meaux, Meaux

Chu Brabois, Nancy

Chu Hotel Dieu, Nantes

Hôpital de l'archet I, Nice

Hôpital COCHIN, Paris

Hôpital St Louis, Paris

CH Saint Jean, Perpignan

CHU Poitiers, Poitiers

CH René Dubos, Pontoise

Hôpital Pontchaillou, Rennes

Centre Henri Becquerel, Rouen

CH St Malo, St-Malo

CHU Toulouse, Toulouse

Hôpital Bretonneau, Tours

CH Princesse Grâce, Monaco

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

lead

University Hospital, Toulouse

OTHER

NCT02689622 - PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | Biotech Hunter | Biotech Hunter